Filing Details
- Accession Number:
- 0001104659-23-096582
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-08-29 17:00:48
- Reporting Period:
- 2023-08-25
- Accepted Time:
- 2023-08-29 17:00:48
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1356576 | Supernus Pharmaceuticals Inc. | SUPN | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1539494 | Tillotson Tami Martin | C/O Supernus Pharmaceuticals, Inc., 9715 Key West Avenue Rockville MD 20850 | Sr. V.p., Regulatory Affairs | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2023-08-25 | 5,135 | $31.59 | 85,249 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct |
Footnotes
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.38 to $31.92, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
- Includes an aggregate of 350 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan.
Billionaire Hedge Funds
